MI-389

• CAT Number: I032249
• CAS Number: 2222635-92-7
• Molecular Formula: C35H35FN6O6
• Molecular Weight: 654.69
• Purity: ≥95%
• Synonyms: N-[6-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]hexyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
• InChI: InChI=1S/C35H35FN6O6/c1-18-26(17-23-22-16-20(36)10-11-24(22)40-31(23)44)39-19(2)29(18)33(46)38-15-6-4-3-5-14-37-25-9-7-8-21-30(25)35(48)42(34(21)47)27-12-13-28(43)41-32(27)45/h7-11,16-17,27,37,39H,3-6,12-15H2,1-2H3,(H,38,46)(H,40,44)(H,41,43,45)/b23-17-
• InChIKey: VXBLUAKQWQJPAD-QJOMJCCJSA-N
• SMILES: CC1=C(NC(=C1C(=O)NCCCCCCNC2=CC=CC3=C2C(=O)N(C3=O)C4CCC(=O)NC4=O)C)/C=C\5/C6=C(C=CC(=C6)F)NC5=O

MI-389（Cat No.:I032249）is a potent small-molecule inhibitor of the menin-MLL (mixed-lineage leukemia) protein–protein interaction, a critical driver in MLL-rearranged leukemias. By disrupting the binding of menin to MLL fusion proteins, MI-389 impairs the transcription of oncogenic target genes such as HOXA9 and MEIS1, leading to differentiation and apoptosis of leukemia cells. It is widely used in preclinical hematologic cancer research to explore epigenetic regulation, transcriptional control, and targeted therapy development for acute leukemias with MLL rearrangements. MI-389 supports the advancement of menin inhibitors as promising treatments in epigenetically driven cancers.